Cargando…

Novel Outcome Measures for Clinical Trials in Cystic Fibrosis

Cystic fibrosis (CF) is a common inherited condition caused by mutations in the gene encoding the CF transmembrane regulator protein. With increased understanding of the molecular mechanisms underlying CF and the development of new therapies there comes the need to develop new outcome measures to as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tiddens, Harm AWM, Puderbach, Michael, Venegas, Jose G, Ratjen, Felix, Donaldson, Scott H, Davis, Stephanie D, Rowe, Steven M, Sagel, Scott D, Higgins, Mark, Waltz, David A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2015
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4365726/ https://www.ncbi.nlm.nih.gov/pubmed/25641878 http://dx.doi.org/10.1002/ppul.23146

Ejemplares similares

Aspergillus-related lung disease in people with cystic fibrosis: can imaging help us to diagnose disease?
por: Lv, Qianting, et al.
Publicado: (2021)

Shifting Landscape of Airway Infection in Early Cystic Fibrosis
por: Hoppe, Jordana E., et al.
Publicado: (2019)

Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial
por: Nichols, David P., et al.
Publicado: (2021)

Designing Clinical Trials for Anti-Inflammatory Therapies in Cystic Fibrosis
por: Perrem, Lucy, et al.
Publicado: (2020)

Letting It All Out: Neutrophils in Early Cystic Fibrosis Airway Inflammation
por: Perrem, Lucy, et al.
Publicado: (2019)

Characteristics and outcomes of oral antibiotic treated pulmonary exacerbations in children with cystic fibrosis()
por: Hoppe, Jordana E., et al.
Publicado: (2018)

Home videos of cystic fibrosis patients using tobramycin inhalation powder: Relation of flow and cough
por: Meerburg, Jennifer J., et al.
Publicado: (2019)

Reliability of Quantitative Real-Time PCR for Bacterial Detection in Cystic Fibrosis Airway Specimens
por: Zemanick, Edith T., et al.
Publicado: (2010)

Inflammation and Airway Microbiota during Cystic Fibrosis Pulmonary Exacerbations
por: Zemanick, Edith T., et al.
Publicado: (2013)

Longitudinal lung clearance index and association with structural lung damage in children with cystic fibrosis
por: Svedberg, Marcus, et al.
Publicado: (2023)

Pulmonary exacerbations and clinical outcomes in a longitudinal cohort of infants and preschool children with cystic fibrosis
por: Hoppe, Jordana E., et al.
Publicado: (2017)

Chest radiography and computed tomography imaging in cystic fibrosis: current challenges and new perspectives
por: Ciet, Pierluigi, et al.
Publicado: (2022)

Perspectives on the translation of in-vitro studies to precision medicine in Cystic Fibrosis
por: Dumas, Marie-Pier, et al.
Publicado: (2021)

L-Ornithine Derived Polyamines in Cystic Fibrosis Airways
por: Grasemann, Hartmut, et al.
Publicado: (2012)

The Equitable Implementation of Cystic Fibrosis Personalized Medicines in Canada
por: Shemie, Genevieve, et al.
Publicado: (2021)

Clinical characteristics of people with cystic fibrosis and frequent fungal infection
por: Poore, T. Spencer, et al.
Publicado: (2021)

Airway disease on chest computed tomography of preschool children with cystic fibrosis is associated with school‐age bronchiectasis
por: Bouma, Nynke R., et al.
Publicado: (2019)

Surfactant Protein A in Cystic Fibrosis: Supratrimeric Structure and Pulmonary Outcome
por: Griese, Matthias, et al.
Publicado: (2012)

Decreased systemic bioavailability of L-arginine in patients with cystic fibrosis
por: Grasemann, Hartmut, et al.
Publicado: (2006)

The development of bronchiectasis on chest computed tomography in children with cystic fibrosis: can pre-stages be identified?
por: Tepper, Leonie A., et al.
Publicado: (2016)

Paediatric lung imaging: the times they are a-changin'
por: Tiddens, Harm A.W.M, et al.
Publicado: (2018)

The clinical impact of Lumacaftor-Ivacaftor on structural lung disease and lung function in children aged 6–11 with cystic fibrosis in a real-world setting
por: McNally, Paul, et al.
Publicado: (2023)

Evaluating the Impact of Stopping Chronic Therapies after Modulator Drug Therapy in Cystic Fibrosis: The SIMPLIFY Clinical Trial Study Design
por: Mayer-Hamblett, Nicole, et al.
Publicado: (2021)

Sequential analysis of surfactant, lung function and inflammation in cystic fibrosis patients
por: Griese, Matthias, et al.
Publicado: (2005)

Early childhood lung function is a stronger predictor of adolescent lung function in cystic fibrosis than early Pseudomonas aeruginosa infection
por: Pittman, Jessica E., et al.
Publicado: (2017)

Structure and function of small airways in asthma patients revisited
por: van den Bosch, Wytse B., et al.
Publicado: (2021)

Diagnosis of bronchiectasis and airway wall thickening in children with cystic fibrosis: Objective airway-artery quantification
por: Kuo, Wieying, et al.
Publicado: (2017)

The effect of CFTR modulators on structural lung disease in cystic fibrosis
por: Mok, L. Clara, et al.
Publicado: (2023)

Correlation of Electrophysiological and Fluorescence-Based Measurements of Modulator Efficacy in Nasal Epithelial Cultures Derived from People with Cystic Fibrosis
por: Gunawardena, Tarini N. A., et al.
Publicado: (2023)

Pulmonary Emphysema in Cystic Fibrosis Detected by Densitometry on Chest Multidetector Computed Tomography
por: Wielpütz, Mark O., et al.
Publicado: (2013)

Testing Two Different Doses of Tiotropium Respimat® in Cystic Fibrosis: Phase 2 Randomized Trial Results
por: Bradley, Judy M., et al.
Publicado: (2014)

The radiological diagnosis of bronchiectasis: what's in a name?
por: Tiddens, Harm A.W.M., et al.
Publicado: (2020)

Predicting return of lung function after a pulmonary exacerbation using the cystic fibrosis respiratory symptom diary-chronic respiratory infection symptom scale
por: Gill, Eliana R., et al.
Publicado: (2023)

Weight increase in people with cystic fibrosis on CFTR modulator therapy is mainly due to increase in fat mass
por: Mouzaki, Marialena, et al.
Publicado: (2023)

Management of respiratory tract exacerbations in people with cystic fibrosis: Focus on imaging
por: Landini, Nicholas, et al.
Publicado: (2023)

Safety of intravenous tobramycin in combination with a variety of anti-pseudomonal antibiotics in children with cystic fibrosis
por: Deschamp, Ashley R, et al.
Publicado: (2017)

Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: Lessons learned from the first ataluren phase 3 study
por: Tiddens, Harm A. W. M., et al.
Publicado: (2020)

Patient-Specific Modeling of Regional Antibiotic Concentration Levels in Airways of Patients with Cystic Fibrosis: Are We Dosing High Enough?
por: Bos, Aukje C., et al.
Publicado: (2015)

Pulmonary artery enlargement and cystic fibrosis pulmonary exacerbations: a cohort study
por: Wells, J. Michael, et al.
Publicado: (2016)

Effect of airway clearance therapies on mucociliary clearance in adults with cystic fibrosis: A randomized controlled trial
por: Trimble, Aaron, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pco0l6p396698g32hra6385mel